INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09888471
Filing Date		2001-06-25
First Named Inventor	BAS	SETT
Art Unit		2174
Examiner Name Boris		M. Pesin
Attorney Docket Number		AUS920000714US1

	U.S.PATENTS						move
Examiner Initial*	Cite No	Patent Number	Kind Code ¹			Pages,Co Relevant I Figures A	umns,Lines where Passages or Relevant opear
	1	6751626		2004-06-15	Brown et al.		
	2	6956979		2005-10-18	Janakiraman et al		
3 6370566		6370566		2002-04-09	Discolo et al		
	4	6757530		2004-06-29	Rouse et al.		
If you wisl	h to ac	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.		Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Re	move
Examiner Cite Publication Number Kind Code		Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document		umns,Lines where Passages or Relevant opear	
	1	20020196280		2002-12-26	Bassette et al.		
	2	20030004856		2003-01-02	Brown et al.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09888471
Filing Date		2001-06-25
First Named Inventor BASS		SETT
Art Unit		2174
Examiner Name	Boris	M. Pesin
Attorney Docket Numb	er	AUS920000714US1

	3	20030061303		2003-0	3-27	Brown et al				
	4	20030069899		2003-0	2003-04-10 Brown et al.					
	5	20030131059		2003-0	7-10	Brown et al.				
	6	20010014866		2001-08-16 Conmy et al						
	7	20010014867		2006-07-18		Conmy				
	8	20030088479		2003-0	5-08	Wooten et al.				
	9	20010049617		2001-1	2-06	Berenson et a				
If you wish	h to a	dd additional U.S. Publi						d butto		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4		Name of Patentee Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	TE
	1									
If you wish	h to a	dd additional Foreign P						button	_	
			NON	-PATE	NT LITE	RATURE DO	CUMENTS		Remove	

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

Initials*	No	(book, magazine, journal, senal, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.
	1	"IBM Lotus: Calendaring is on the Agenda", Computer Reetler News, N174, pp. 119-122, Dec 9 1996
	2	
If you wis	h to a	dd additional non-patent literature document citation information please click the Add button Add
		EXAMINER SIGNATURE
Examine	r Signa	ture Date Considered
	ICD. I	THE PARTY OF THE P

16e Kinz Code of USPTO Petern Documents at yeary USPTO_CODY or MEPE 90.04. 2 littler office that issued the document, by the two letter code (MIPO Standard ST.3). 3 "explainese patient focument, the includation of the year of the register or many precised her evial number of the patient document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if Empirish targinacies the instantation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09888471
Filing Date		2001-06-25
First Named Inventor	BASS	SETT
Art Unit		2174
Examiner Name	Boris	M. Pesin
Attorney Docket Numb	er	AUS920000714US1

CERTIFICATION STATEMENT

Please see 37	CFR 1	.97 and	1.98 to make the	appropriate	selection(s)	
---------------	-------	---------	------------------	-------------	------------	----	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement See 37 CFR 1 97(e)(2)

- See attached certification statement
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature

Registration Number

Signature	/David Victor/	Date (YYYY-MM-DD)	2006-07-19
Name/Print	David W. Victor	Registration Number	39867

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria. VA 22313-1450

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan, Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the patient of th

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing impaction of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was fled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to published application, an application pare to published application and application and applications or an insurance of the published application and applications.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.